top of page

Quick Facts: What is Yutrepia?

Jun 3, 2025
1 min read

What it is

Yutrepia is a new drug: an inhaled form of treprostinil, a prostacyclin analogue. It was just approved by the Food and Drug Administration in the USA.


Who it's for

Yutrepia is approved in the USA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), to improve exercise ability. Originally, it was approved only for PAH patients, but the company then asked for approval for use in PH-ILD patients as well. It's not approved for other types of PH because it dilates blood vessels, which could lead to dangerously low blood pressure in people whose pulmonary hypertension is associated with other heart or lung issues.


What we know

It's designed to be easy to inhale while still reaching deep in the lungs. Inhaling the drug gets it right where it needs to be -- in the lungs -- so more of it stays there and less of it ends up in the rest of the body. Patients in clinical trials in the USA preferred it to another inhaled version of treprostinil (Tyvaso) that's already available. Tyvaso and Yutrepia will be the same price -- about US$25,000 per month.


What we don't know

We don't know whether Liquidia will seek approval for Yutrepia in Canada. This means Yutrepia won't be available in Canada unless and until they seek Health Canada approval. No inhaled or oral prostacyclin analogues have been approved in Canada yet, including Tyvaso.

 
 
 

70 Comments


Thank you for sharing these helpful facts about Yutrepia. For anyone interested in browser games, check out Deltarune Fight Simulator.

Like

The note that Yutrepia is approved in the USA for PAH and PH-ILD, but not yet in Canada, is the useful part of this summary. I also keep a short list of easy browser games for downtime here: GachaPlay.

Like

Helpful overview of what Yutrepia is and who it is approved for in the USA. The note on exercise ability made me think of low-impact practice for balance and daily energy: Taichi Walking.

Like

This is a clear summary of Yutrepia, the inhaled treprostinil approved in the USA for PAH and PH-ILD. I bookmarked a practice resource here: G1 Practice.

Like

192.168.1.1 is a useful term for readers researching local router configuration. Clear documentation can help users understand administrative interfaces, review available network settings, and recognize why the correct address can vary according to the router model and network environment.

Like

PHA Canada

408 - 55 Water Street

Office 8928

Vancouver, BC, V6B 1A1

Email: info@phacanada.ca

Phone: 604-682-1036

Toll Free: 1-877-774-2226

Charitable Registration # 872050224RR0001

  • Instagram
  • Facebook
  • X
  • LinkedIn
  • Youtube

Copyright 2025 PHA CANADA, ALL RIGHTS RESERVED   |   Website created by Creativibe

bottom of page